ADL | adalimumab |
AAA | Anti-adalimumab antibodies |
SPR | Surface plasmon resonance |
TNF-α | Tumor necrosis factor-alpha (TNF-α) |
FDA | Food and Drug Administration |
EMA | European Medicines Agency |
JIA | Juvenile Idiopathic Arthritis |
NHS | N-hydroxysuccinimide |
EDC | 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide |
RU | Resonance Units |
MTX | Methotrexate |